Since January 2020, Elsevier has established a COVID-19 resource center on Elsevier Connect, providing free information in English and Mandarin about the novel coronavirus. The company has granted permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. On May 19, 2021, the Delta Variant of Concern (VOC) became the dominant strain in Scotland. The study used ThermoFisher’s TaqPath RT-PCR to analyze samples, identifying 97% of S gene-positive cases as the Delta variant. The EAVE II platform, a Scotland-wide COVID-19 surveillance system, was utilized to track and forecast the epidemiology of COVID-19, inform risk stratification, and assess vaccine effectiveness. The analysis covered the period from April 1 to June 6, 2021, and found that 377 out of 19,543 confirmed infections were hospitalized for COVID-19, with 35.5% of these cases being S gene-positive. S gene-positive cases were associated with an increased risk of hospital admission, especially in those with multiple comorbidities. Both the Oxford-AstraZeneca and Pfizer-BioNTech vaccines were effective in reducing the risk of infection and hospitalization, but the vaccine effect was less pronounced in S gene-positive cases compared to S gene-negative cases. The study highlights the importance of timely and accessible data in managing the pandemic and the need for better data collection and transparency.Since January 2020, Elsevier has established a COVID-19 resource center on Elsevier Connect, providing free information in English and Mandarin about the novel coronavirus. The company has granted permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. On May 19, 2021, the Delta Variant of Concern (VOC) became the dominant strain in Scotland. The study used ThermoFisher’s TaqPath RT-PCR to analyze samples, identifying 97% of S gene-positive cases as the Delta variant. The EAVE II platform, a Scotland-wide COVID-19 surveillance system, was utilized to track and forecast the epidemiology of COVID-19, inform risk stratification, and assess vaccine effectiveness. The analysis covered the period from April 1 to June 6, 2021, and found that 377 out of 19,543 confirmed infections were hospitalized for COVID-19, with 35.5% of these cases being S gene-positive. S gene-positive cases were associated with an increased risk of hospital admission, especially in those with multiple comorbidities. Both the Oxford-AstraZeneca and Pfizer-BioNTech vaccines were effective in reducing the risk of infection and hospitalization, but the vaccine effect was less pronounced in S gene-positive cases compared to S gene-negative cases. The study highlights the importance of timely and accessible data in managing the pandemic and the need for better data collection and transparency.